Baculovirus P35 protein: an overview of its applications across multiple therapeutic and biotechnological arenas.
Baculovirus immediate early P35 protein is well known for its anti-apoptotic as well as anti-oxidant properties. Mechanism of action of P35 involves inhibition of a vast range of initiator to executioner class of caspases. In addition, P35's role in inhibiting oxidant-induced mitochondrial damage, primarily in the apoptotic pathway, has also been extensively investigated. Elucidation of P35's functions during regulation of programmed cell death (PCD) has led to a renewed focus on exploiting this basic knowledge for clinical and other related applications. This review outlines specific biochemical and genetic pathways where P35 intervenes and regulates rate-limiting steps in the apoptotic signaling cascade. Research efforts are underway to utilize P35 as an agent in regulating apoptosis and under certain circumstances, also explore the therapeutic potential of its anti-oxidant features. One of the major outcomes of recent studies include significantly improved effectiveness of cytochrome P450 directed enzyme pro-drug delivery tools when used in conjunction with P35, which may help in alleviating drug resistance in tumor cells and simultaneously prolonging the cytotoxic effects of anti-cancer drugs. Moreover, applied research carried out recently in the fields of diabetes, ischemia-induced neuronal cell death, experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS), inflammatory arthritis, cardiovascular and ocular disorders illustrate P35's utilization across diverse therapeutic areas and will certainly make it an attractive biomolecule for the discovery research.
Sahdev
Sudhir
S
Dept. of Biotechnology & Bioinformatics, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, India. sudhir.sahdev@ranbaxy.com
Saini
Kulvinder Singh
KS
Hasnain
Seyed E
SE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001709:Biotechnology / Q000379:methods; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000502:physiology* / Q000627:therapeutic use*; D051379:Mice; D014764:Viral Proteins / Q000502:physiology* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D000975:Antioxidants; D051034:Inhibitor of Apoptosis Proteins; D014764:Viral Proteins; C086430:inhibitor of apoptosis, Nucleopolyhedrovirus